Xencor, Inc. (NASDAQ:XNCR) Receives $36.56 Consensus Target Price from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given an average rating of “Buy” by the nine ratings firms that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $36.56.

Several research analysts have commented on XNCR shares. BMO Capital Markets reissued an “outperform” rating and set a $34.00 target price (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Wells Fargo & Company started coverage on shares of Xencor in a research report on Thursday, December 12th. They set an “overweight” rating and a $37.00 price objective for the company. Royal Bank of Canada raised their target price on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. Wedbush reaffirmed an “outperform” rating and set a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. increased their price target on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th.

Insider Buying and Selling

In other news, CEO Bassil I. Dahiyat sold 3,366 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total transaction of $80,851.32. Following the completion of the sale, the chief executive officer now directly owns 352,615 shares in the company, valued at $8,469,812.30. This represents a 0.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction on Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the transaction, the vice president now directly owns 200,104 shares of the company’s stock, valued at $4,698,441.92. This represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 136,050 shares of company stock valued at $3,277,609 in the last three months. Insiders own 5.23% of the company’s stock.

Institutional Trading of Xencor

Large investors have recently bought and sold shares of the business. Quarry LP acquired a new stake in Xencor in the second quarter worth $36,000. GAMMA Investing LLC boosted its position in shares of Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV grew its stake in shares of Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 1,213 shares during the period. Rockefeller Capital Management L.P. acquired a new stake in shares of Xencor in the 3rd quarter valued at about $205,000. Finally, XTX Topco Ltd bought a new stake in Xencor in the 2nd quarter valued at about $196,000.

Xencor Stock Performance

Shares of NASDAQ:XNCR opened at $20.60 on Thursday. Xencor has a 1 year low of $15.31 and a 1 year high of $27.24. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -6.44 and a beta of 0.72. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company’s 50 day simple moving average is $24.18 and its 200 day simple moving average is $20.99.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. During the same quarter last year, the company posted ($0.40) EPS. The company’s revenue for the quarter was down 81.9% compared to the same quarter last year. As a group, research analysts predict that Xencor will post -3.71 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.